Pharma Deals Review, Vol 2007, No 88 (2007)

Font Size:  Small  Medium  Large

Meda Acquires North Amercian Rights to Potential Blockbuster from BDSI

Business Review Editor

Abstract


Meda entered into an exclusive and perpetual license agreement with BioDelivery Sciences International (BDSI) to market BEMA(TM) Fentanyl for the treatment of breakthrough cancer pain in Canada, Mexico and US. The total value of the deal is US$90 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.